Moreover, although our study indicated that targeting UCP2 alone may be an innovative strategy for cancer therapy, earlier studies have shown that the chemosensitivity was varying among different HCC cell lines [26]. This evidence concerns the gene UCP2 and hepatocellular carcinoma.